DB16115Investigational
Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).
- Mechanism
- Curator reviewed
Pharmacologically active on Interleukin-23
- Also known as
- Immunoglobulin g2, anti-(human interleukin 23) (human monoclonal medi2070 heavy chain), disulfide with human monoclonal medi2070 .lambda.-chain, dimer
- Code names
- MEDI-2070
Resolves to
Compound
What you can answer from here — as of July 08, 2026
Which companies are running trials of Brazikumab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account